Modeling Alzheimer’s disease in transgenic rats

Molecular Neurodegeneration

A Claudio Cuello²  Sonia Do Carmo¹ 

[1] Department of Pharmacology and Therapeutics, McGill University, 3655 Promenade Sir-William-Osler, Room 1325, Montreal, Quebec H3G 1Y6, Canada;Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec H3A 2B4, Canada

关键词: Neuronal loss;    Tau;    Mature plaques;    Intracellular;    Amyloid;    Early pathology;    Behavior;    Transgenic;    Rat;    Alzheimer’s disease;   

Others  :  862076
DOI  :  10.1186/1750-1326-8-37

 received in 2013-07-05, accepted in 2013-09-28,  发布年份 2013

【 摘 要 】

Alzheimer’s disease (AD) is the most common form of dementia. At the diagnostic stage, the AD brain is characterized by the accumulation of extracellular amyloid plaques, intracellular neurofibrillary tangles and neuronal loss. Despite the large variety of therapeutic approaches, this condition remains incurable, since at the time of clinical diagnosis, the brain has already suffered irreversible and extensive damage. In recent years, it has become evident that AD starts decades prior to its clinical presentation. In this regard, transgenic animal models can shed much light on the mechanisms underlying this “pre-clinical” stage, enabling the identification and validation of new therapeutic targets. This paper summarizes the formidable efforts to create models mimicking the various aspects of AD pathology in the rat. Transgenic rat models offer distinctive advantages over mice. Rats are physiologically, genetically and morphologically closer to humans. More importantly, the rat has a well-characterized, rich behavioral display. Consequently, rat models of AD should allow a more sophisticated and accurate assessment of the impact of pathology and novel therapeutics on cognitive outcomes.

【 授权许可】

   
2013 Do Carmo and Cuello; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Callaway E: Alzheimer’s drugs take a new tack. Nature 2012, 489:13-14.
• [2]Cuello AC: Overview of the Alzheimer’s Disease Pathology and Potential Therapeutic Targets. In Pharmacological Mechanisms in Alzheimer's Therapeutics. Edited by Cuello AC. New York: Springer Science and Business Media; 2007:1-27.
• [3]Hardy JA, Mann DM, Wester P, Winblad B: An integrative hypothesis concerning the pathogenesis and progression of Alzheimer’s disease. Neurobiol Aging 1986, 7:489-502.
• [4]Selkoe DJ: The molecular pathology of Alzheimer’s disease. Neuron 1991, 6:487-698.
• [5]Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R: Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991, 30:572-580.
• [6]Barrientos RM, Higgins EA, Sprunger DB, Watkins LR, Rudy JW, Maier SF: Memory for context is impaired by a post context exposure injection of interleukin-1 beta into dorsal hippocampus. Behav Brain Res 2002, 134:291-298.
• [7]Yaffe K, Lindquist K, Penninx BW, Simonsick EM, Pahor M, Kritchevsky S, Launer L, Kuller L, Rubin S, Harris T: Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 2003, 61:76-80.
• [8]Dandrea MR, Reiser PA, Gumula NA, Hertzog BM, Andrade-Gordon P: Application of triple immunohistochemistry to characterize amyloid plaque-associated inflammation in brains with Alzheimer’s disease. Biotech Histochem 2001, 76:97-106.
• [9]Mehlhorn G, Hollborn M, Schliebs R: Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. Int J Dev Neurosci 2000, 18:423-431.
• [10]Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC: Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 2012, 367:795-804.
• [11]Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ: Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 2010, 9:119-128.
• [12]Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH: Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011, 7:280-892.
• [13]Hsiao KK, Borchelt DR, Olson K, Johannsdottir R, Kitt C, Yunis W, Xu S, Eckman C, Younkin S, Price D, Iadecola C, Brent Clark H, Carlson G: Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 1995, 15:1203-1218.
• [14]Quon D, Wang Y, Catalano R, Scardina JM, Murakami K, Cordell B: Formation of beta-amyloid protein deposits in brains of transgenic mice. Nature 1991, 352:239-241.
• [15]Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah F, McConologue L, Montoya-Zavala M, Mucke L, Paganini L, Penniman E, Power M, Schenk D, Seubert P, Snyder B, Soriano F, Tan H, et al.: Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995, 373:523-527.
• [16]Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O’Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K, Duff K: Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 1998, 4:97-100.
• [17]Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M: Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 2000, 25:402-405.
• [18]Charreau B, Tesson L, Soulillou JP, Pourcel C, Anegon I: Transgenesis in rats: technical aspects and models. Transgenic Res 1996, 5:223-234.
• [19]Tesson L, Cozzi J, Ménoret S, Rémy S, Usal C, Fraichard A, Anegon I: Transgenic modifications of the rat genome. Transgenic Res 2005, 14:531-546.
• [20]Tong C, Li P, Wu NL, Yan Y, Ying QL: Production of p53 gene knockout rats by homologous recombination in embryonic stem cells. Nature 2010, 467:211-213.
• [21]Gibbs RA, Weinstock GM, Metzker ML, Muzny DM, Sodergren EJ, Scherer S, Scott G, Steffen D, Worley KC, Burch PE, Okwuonu G, Hines S, Lewis L, DeRamo C, Delgado O, Dugan-Rocha S, Miner G, Morgan M, Hawes A, Gill R, Celera Holt RA, Adams MD, Amanatides PG, Baden-Tillson H, Barnstead M, Chin S, Evans CA, Ferriera S, Fosler C, et al.: Genome sequence of the Brown Norway rat yields insights into mammalian evolution. Nature 2004, 428:493-521.
• [22]Jacob HJ, Kwitek AE: Rat genetics: attaching physiology and pharmacology to the genome. Nat Rev Genet 2002, 3:33-42.
• [23]Lin JH: Species similarities and differences in pharmacokinetics. Drug Metab Dispos 1995, 23:1008-1021.
• [24]Hanes J, Zilka N, Bartkova M, Caletkova M, Dobrota D, Novak M: Rat tau proteome consists of six tau isoforms: implication for animal models of human tauopathies. J Neurochem 2009, 108:1167-1176.
• [25]McLean JW, Fukazawa C, Taylor JM: Rat apolipoprotein E mRNA. Cloning and sequencing of double-stranded cDNA. J Biol Chem 1983, 258:8993-9000.
• [26]Rajavashisth TB, Kaptein JS, Reue KL, Lusis AJ: Evolution of apolipoprotein E: mouse sequence and evidence for an 11-nucleotide ancestral unit. Proc Natl Acad Sci U S A 1985, 82:8085-8089.
• [27]Tran TN, Kim SH, Gallo C, Amaya M, Kyees J, Narayanaswami V: Biochemical and biophysical characterization of recombinant rat apolipoprotein E: similarities to human apolipoprotein E3. Arch Biochem Biophys 2013, 529:18-25.
• [28]Whishaw IQ, Metz GA, Kolb B, Pellis SM: Accelerated nervous system development contributes to behavioral efficiency in the laboratory mouse: a behavioral review and theoretical proposal. Dev Psychobiol 2001, 39:151-170.
• [29]Taravini IR, Chertoff M, Cafferata EG, Courty J, Murer MG, Pitossi FJ, Gershanik OS: Pleiotrophin over-expression provides trophic support to dopaminergic neurons in parkinsonian rats. Mol Neurodegener 2011, 6:40. BioMed Central Full Text
• [30]Kitamura Y, Watanabe S, Taguchi M, Takagi K, Kawata T, Takahashi-Niki K, Yasui H, Maita H, Iguchi-Ariga SM, Ariga H: Neuroprotective effect of a new DJ-1-binding compound against neurodegeneration in Parkinson’s disease and stroke model rats. Mol Neurodegener 2011, 6:48. BioMed Central Full Text
• [31]Nuber S, Harmuth F, Kohl Z, Adame A, Trejo M, Schönig K, Zimmermann F, Bauer C, Casadei N, Giel C, Calaminus C, Pichler BJ, Jensen PH, Müller CP, Amato D, Kornhuber J, Teismann P, Yamakado H, Takahashi R, Winkler J, Masliah E, Riess O: A progressive dopaminergic phenotype associated with neurotoxic conversion of α-synuclein in BAC-transgenic rats. Brain 2013, 136:412-432.
• [32]von Hörsten S, Schmitt I, Nguyen HP, Holzmann C, Schmidt T, Walther T, Bader M, Pabst R, Kobbe P, Krotova J, Stiller D, Kask A, Vaarmann A, Rathke-Hartlieb S, Schulz JB, Grasshoff U, Bauer I, Vieira-Saecker AM, Paul M, Jones L, Lindenberg KS, Landwehrmeyer B, Bauer A, Li XJ, Riess O: Transgenic rat model of Huntington’s disease. Hum Mol Genet 2003, 12:617-624.
• [33]Howland DS, Liu J, She Y, Goad B, Maragakis NJ, Kim B, Erickson J, Kulik J, DeVito L, Psaltis G, DeGennaro LJ, Cleveland DW, Rothstein JD: Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutantmediated amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2002, 99:1604-1609.
• [34]Klein RL, Dayton RD, Tatom JB, Diaczynsky CG, Salvatore MF: Tau expression levels from various adeno-associated virus vector serotypes produce graded neurodegenerative disease states. Eur J Neurosci 2008, 27:1615-1625.
• [35]Zilka N, Filipcik P, Koson P, Fialova L, Skrabana R, Zilkova M, Rolkova G, Kontsekova E, Novak M: Truncated tau from sporadic Alzheimer’s disease suffices to drive neurofibrillary degeneration in vivo. FEBS Lett 2006, 580:3582-3588.
• [36]Mullins JJ, Peters J, Ganten D: Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 1990, 344:541-544.
• [37]Herrera VL, Makrides SC, Xie HX, Adari H, Krauss RM, Ryan US, Ruiz-Opazo N: Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human choles-teryl ester transfer protein. Nat Med 1999, 5:1383-1389.
• [38]Gilad GM, Gilad VH: Age-related reductions in brain cholinergic and dopaminergic indices in two rat strains differing in longevity. Brain Res 1987, 408:247-250.
• [39]Greene E, Naranjo JN: Degeneration of hippocampal fibers and spatial memory deficits in the aged rat. Neurobiol Aging 1987, 8:35-43.
• [40]Anderson JJ, Holtz G, Baskin PP, Wang R, Mazzarelli L, Wagner SL, Menzaghi F: Reduced cerebrospinal fluid levels of alpha-secretase-cleaved amyloid precursor protein in aged rats: correlation with spatial memory deficits. Neuroscience 1999, 93:1409-1420.
• [41]Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR: Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science 1982, 215:1237-1239.
• [42]Quirion R, Martel JC, Robitaille Y, Etienne P, Wood P, Nair NP, Gauthier S: Neurotransmitter and receptor deficits in senile dementia of the Alzheimer type. Can J Neurol Sci 1986, 13(Suppl 4):503-510.
• [43]Bierer LM, Haroutunian V, Gabriel S, Knott PJ, Carlin LS, Purohit DP, Perl DP, Schmeidler J, Kanof P, Davis KL: Neurochemical correlates of dementia severity in Alzheimer’s disease: relative importance of the cholinergic deficits. J Neurochem 1995, 64:749-760.
• [44]Giacobini E: Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol Res 2004, 50:433-440.
• [45]Pazzagli A, Pepeu G: Amnesic properties of scopolamine and brain acetylcholine in the rat. Int J Neuropharmacol 1965, 4:291-299.
• [46]Nitta A, Katono Y, Itoh A, Hasegawa T, Nabeshima T: Nicotine reverses scopolamine-induced impairment of performance in passive avoidance task in rats through its action on the dopaminergic neuronal system. Pharmacol Biochem Behav 1994, 49:807-812.
• [47]McGaughy J, Everitt BJ, Robbins TW, Sarter M: The role of cortical cholinergic afferent projections in cognition: impact of new selective immunotoxins. Behav Brain Res 2000, 115:251-263.
• [48]Rossner S, Wörtwein G, Gu Z, Yu J, Schliebs R, Bigl V, Perez-Polo JR: Cholinergic control of nerve growth factor in adult rats: evidence from cortical cholinergic deafferentation and chronic drug treatment. J Neurochem 1997, 69:947-953.
• [49]Iwata A, Chen XH, McIntosh TK, Browne KD, Smith DH: Long-term accumulation of amyloid-beta in axons following brain trauma without persistent upregulation of amyloid precursor protein genes. J Neuropathol Exp Neurol 2002, 61:1056-1068.
• [50]Liu J, Zhang Z, Li JT, Zhu YH, Zhou HL, Liu S, Wang TH: Effects of NT-4 gene modified fibroblasts transplanted into AD rats. Neurosci Lett 2009, 466:1-5.
• [51]Feng Z, Cheng Y, Zhang JT: Long-term effects of melatonin or 17 beta-estradiol on improving spatial memory performance in cognitively impaired, ovariectomized adult rats. J Pineal Res 2004, 37:198-206.
• [52]Sinigaglia-Coimbra R, Cavalheiro EA, Coimbra CG: Postischemic hyperthermia induces Alzheimer-like pathology in the rat brain. Acta Neuropathol 2002, 103:444-452.
• [53]Glenner GG, Wong CW: Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984, 120:885-890.
• [54]Pike CJ, Walencewicz AJ, Glabe CG, Cotman CW: Aggregation-related toxicity of synthetic beta-amyloid protein in hippocampal cultures. Eur J Pharmacol 1991, 207:367-368.
• [55]Harkany T, O’Mahony S, Keijser J, Kelly JP, Kónya C, Borostyánkoi ZA, Görcs TJ, Zarándi M, Penke B, Leonard BE, Luiten PG: Beta-amyloid(1–42)-induced cholinergic lesions in rat nucleus basalis bidirectionally modulate serotonergic innervation of the basal forebrain and cerebral cortex. Neurobiol Dis 2001, 8:667-678.
• [56]Li DB, Tang J, Fan XT, Song M, Xu HW, Bai Y: Comparative study of histopathology changes between the PS1/APP double transgenic mouse model and Abeta1-40 -injected rat model of Alzheimer disease. Neurosci Bull 2006, 22:52-57.
• [57]Nag S, Yee BK, Tang F: Chronic intracerebroventricular infusion of beta-amyloid (1–40) results in a selective loss of neuropeptides in addition to a reduction in choline acetyltransferase activity in the cortical mantle and hippocampus in the rat. Ann N Y Acad Sci 1999, 897:420-422.
• [58]Nakamura S, Murayama N, Noshita T, Annoura H, Ohno T: Progressive brain dysfunction following intracerebroventricular infusion of beta(1–42)-amyloid peptide. Brain Res 2001, 912:128-136.
• [59]Gong Y, Meyer EM, Meyers CA, Klein RL, King MA, Hughes JA: Memory-related deficits following selective hippocampal expression of Swedish mutation amyloid precursor protein in the rat. Exp Neurol 2006, 200:371-377.
• [60]Lawlor PA, Bland RJ, Das P, Price RW, Holloway V, Smithson L, Dicker BL, During MJ, Young D, Golde TE: Novel rat Alzheimer’s disease models based on AAV-mediated gene transfer to selectively increase hippocampal Abeta levels. Mol Neurodegener 2007, 2:11. BioMed Central Full Text
• [61]Stozicka Z, Zilka N, Novak P, Kovacech B, Bugos O, Novak M: Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer’s disease. J Neuroinflammation 2010, 7:64. BioMed Central Full Text
• [62]Echeverria V, Ducatenzeiler A, Alhonen L, Janne J, Grant SM, Wandosell F, Muro A, Baralle F, Li H, Duff K, Szyf M, Cuello AC: Rat transgenic models with a phenotype of intracellular Abeta accumulation in hippocampus and cortex. J Alzheimers Dis 2004, 6:209-219.
• [63]Echeverria V, Ducatenzeiler A, Dowd E, Jänne J, Grant SM, Szyf M, Wandosell F, Avila J, Grimm H, Dunnett SB, Hartmann T, Alhonen L, Cuello AC: Altered mitogen-activated protein kinase signaling, tau hyperphosphorylation and mild spatial learning dysfunction in transgenic rats expressing the beta-amyloid peptide intracellularly in hippocampal and cortical neurons. Neuroscience 2004, 29:583-592.
• [64]Lopez EM, Bell KF, Ribeiro-da-Silva A, Cuello AC: Early changes in neurons of the hippocampus and neocortex in transgenic rats expressing intracellular human a-beta. J Alzheimers Dis 2004, 6:421-431.
• [65]Vercauteren FG, Clerens S, Roy L, Hamel N, Arckens L, Vandesande F, Alhonen L, Janne J, Szyf M, Cuello AC: Early dysregulation of hippocampal proteins in transgenic rats with Alzheimer’s disease-linked mutations in amyloid precursor protein and presenilin 1. Brain Res Mol Brain Res 2004, 132:241-259.
• [66]Echeverria V, Ducatenzeiler A, Chen CH, Cuello AC: Endogenous beta-amyloid peptide synthesis modulates cAMP response element-regulated gene expression in PC12 cells. Neuroscience 2005, 135:1193-1202.
• [67]Grant SM, Morinville A, Maysinger D, Szyf M, Cuello AC: Phosphorylation of mitogen-activated protein kinase is altered in neuroectodermal cells overexpressing the human amyloid precursor protein 751 isoform. Brain Res Mol Brain Res 1999, 72:115-120.
• [68]Ruiz-Opazo N, Kosik KS, Lopez LV, Bagamasbad P, Ponce LR, Herrera VL: Attenuated hippocampus-dependent learning and memory decline in transgenic TgAPPswe Fischer-344 rats. Mol Med 2004, 10:36-44.
• [69]Johnson SA, Rogers J, Finch CE: APP-695 transcript prevalence is selectively reduced during Alzheimer’s disease in cortex and hippocampus but not in cerebellum. Neurobiol Aging 1989, 10:755-760.
• [70]Higgins LS, Catalano R, Quon D, Cordell B: Transgenic mice expressing human beta-APP751, but not mice expressing beta-APP695, display early Alzheimer’s disease-like histopathology. Ann N Y Acad Sci 1993, 695:224-227.
• [71]Ho L, Fukuchi K, Younkin SG: The alternatively spliced Kunitz protease inhibitor domain alters amyloid beta protein precursor processing and amyloid beta protein production in cultured cells. J Biol Chem 1996, 271:30929-30934.
• [72]Clarke J, Thornell A, Corbett D, Soininen H, Hiltunen M, Jolkkonen J: Overexpression of APP provides neuroprotection in the absence of functional benefit following middle cerebral artery occlusion in rats. Eur J Neurosci 2007, 26:1845-1852.
• [73]Agca C, Fritz JJ, Walker LC, Levey AI, Chan AW, Lah JJ, Agca Y: Development of transgenic rats producing human beta-amyloid precursor protein as a model for Alzheimer’s disease: transgene and endogenous APP genes are regulated tissue-specifically. BMC Neurosci 2008, 9:28. BioMed Central Full Text
• [74]Rosen RF, Fritz JJ, Dooyema J, Cintron AF, Hamaguchi T, Lah JJ, LeVine H 3rd, Jucker M, Walker LC: Exogenous seeding of cerebral β-amyloid deposition in βAPP-transgenic rats. J Neurochem 2012, 120:660-666.
• [75]Kloskowska E, Pham TM, Nilsson T, Zhu S, Oberg J, Codita A, Pedersen LA, Pedersen JT, Malkiewicz K, Winblad B, Folkesson R, Benedikz E: Cognitive impairment in the Tg6590 transgenic rat model of Alzheimer’s disease. J Cell Mol Med 2010, 14:1816-1823.
• [76]Folkesson R, Malkiewicz K, Kloskowska E, Nilsson T, Popova E, Bogdanovic N, Ganten U, Ganten D, Bader M, Winblad B, Benedikz E: A transgenic rat expressing human APP with the Swedish Alzheimer’s disease mutation. Biochem Biophys Res Commun 2007, 358:777-782.
• [77]Flood DG, Lin YG, Lang DM, Trusko SP, Hirsch JD, Savage MJ, Scott RW, Howland DS: A transgenic rat model of Alzheimer’s disease with extracellular Abeta deposition. Neurobiol Aging 2009, 30:1078-1090.
• [78]Liu L, Orozco IJ, Planel E, Wen Y, Bretteville A, Krishnamurthy P, Wang L, Herman M, Figueroa H, Yu WH, Arancio O, Duff K: A transgenic rat that develops Alzheimer’s disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment. Neurobiol Dis 2008, 31:46-57.
• [79]Teng E, Kepe V, Frautschy SA, Liu J, Satyamurthy N, Yang F, Chen PP, Cole GB, Jones MR, Huang SC, Flood DG, Trusko SP, Small GW, Cole GM, Barrio JR: [F-18]FDDNP microPET imaging correlates with brain Aβ burden in a transgenic rat model of Alzheimer disease: effects of aging, in vivo blockade, and anti-Aβ antibody treatment. Neurobiol Dis 2011, 43:565-575.
• [80]Zahorsky-Reeves J, Lawson G, Chu DK, Schimmel A, Ezell PC, Dang M, Couto M: Maintaining longevity in a triple transgenic rat model of Alzheimer’s disease. J Am Assoc Lab Anim Sci 2007, 46:124.
• [81]Leon WC, Canneva F, Partridge V, Allard S, Ferretti MT, DeWilde A, Vercauteren F, Atifeh R, Ducatenzeiler A, Klein W, Szyf M, Alhonen L, Cuello AC: A novel transgenic rat model with a full Alzheimer’s-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment. J Alzheimers Dis 2010, 20:113-126.
• [82]Lambert MP, Velasco PT, Chang L, Viola KL, Fernandez S, Lacor PN, Khuon D, Gong Y, Bigio EH, Shaw P, De Felice FG, Krafft GA, Klein WL: Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem 2007, 100:23-35.
• [83]Hanzel CE, Pichet-Binette A, Cuello AC: Early inflammatory process in a novel transgenic rat model of Alzheimer’s disease. New Orleans, USA: Society for Neuroscience 2012; 2012.
• [84]Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ: Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med 2008, 14:837-842.
• [85]Nilsen LH, Melø TM, Saether O, Witter MP, Sonnewald U: Altered neurochemical profile in the McGill-R-Thy1-APP rat model of Alzheimer’s disease: a longitudinal in vivo 1 H MRS study. J Neurochem 2012, 123:532-541.
• [86]Parent M, Do Carmo S, Aliaga A, Cuello AC, Gauthier S, Rosa-Neto P: Amyloid accumulation and neurodegeneration in a rat model of Alzheimer’s disease. Miami, USA: 7th Human Amyloid Imaging meeting; 2013.
• [87]Shin M, Gauthier S, Wang S, Parent M, Fonov V, Allard S, Kang MS, Do Carmo S, Cuello AC, Rosa-Neto P: Assessment of hippocampal volumetry in transgenic AD rat. Boston, USA: Alzheimer’s Association International Conference; 2013.
• [88]Parent M, Shin M, Do Carmo S, Aliaga A, Gauthier S, Cuello AC, Rosa-Neto P: Amyloid-induced fMRI resting-state connectivity impairment in a rat model of Alzheimer’s disease. Boston, USA: Alzheimer’s Association International Conference; 2013.
• [89]Blackshear AL, Goetz A, Slayyeh B, Wagner S, Leutgeb JK, Cuello AC, Leutgeb S: Changes in place fields in a transgenic rat model of Alzheimer’s disease precede mnemonic behavioral deficits in the Barnes maze. New Orleans, LA: Society for Neuroscience; 2012.
• [90]Qi Y, Klyubin I, Steffen J, Cuello AC, Fuhrmann M, Rowan MJ: Transgenic Rats Overexpressing Human Amyloid Precursor Protein Show Early-life Impairment of Long-term Potentiation in vivo. Florence, Italy: 11th International Conference on Alzheimer’s and Parkinson’s Diseases; 2013.
• [91]Cohen RM, Rezai-Zadeh K, Weitz TM, Rentsendorj A, Gate D, Spivak I, Bholat Y, Vasilevko V, Glabe CG, Breunig JJ, Rakic P, Davtyan H, Agadjanyan MG, Kepe V, Barrio JR, Bannykh S, Szekely CA, Pechnick RN, Town T: A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss. J Neurosci 2013, 33:6245-6256.
• [92]Mocanu MM, Nissen A, Eckermann K, Khlistunova I, Biernat J, Drexler D, Petrova O, Schönig K, Bujard H, Mandelkow E, Zhou L, Rune G, Mandelkow EM: The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy. J Neurosci 2008, 28:737-748.
• [93]Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, Guimaraes A, Yue M, Lewis J, Carlson G, Hutton M, Ashe KH: Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci 2005, 25:10637-10647.
• [94]Cente M, Filipcik P, Pevalova M, Novak M: Expression of a truncated tau protein induces oxidative stress in a rodent model of tauopathy. Eur J Neurosci 2006, 24:1085-1090.
• [95]Hrnkova M, Zilka N, Minichova Z, Koson P, Novak M: Neurodegeneration caused by expression of human truncated tau leads to progressive neurobehavioural impairment in transgenic rats. Brain Res 2007, 1130:206-213.
• [96]Koson P, Zilka N, Kovac A, Kovacech B, Korenova M, Filipcik P, Novak M: Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load. Eur J Neurosci 2008, 28:239-246.
• [97]Filipcik P, Zilka N, Bugos O, Kucerak J, Koson P, Novak P, Novak M: First transgenic rat model developing progressive cortical neurofibrillary tangles. Neurobiol Aging 2012, 33:1448-1456.
• [98]Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G: Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
• [99]Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Bürki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B: Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A 1997, 94:13287-13292.
• [100]Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, Strome R, Zuker N, Loukides J, French J, Turner S, Lozza G, Grilli M, Kunicki S, Morissette C, Paquette J, Gervais F, Bergeron C, Fraser PE, Carlson GA, George-Hyslop PS, Westaway D: Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 2001, 276:21562-21570.
• [101]Lee KW, Lee SH, Kim H, Song JS, Yang SD, Paik SG, Han PL: Progressive cognitive impairment and anxiety induction in the absence of plaque deposition in C57BL/6inbred mice expressing transgenic amyloid precursor protein. J Neurosci Res 2004, 76:572-580.
• [102]Ferretti MT, Partridge V, Leon WC, Canneva F, Allard S, Arvanitis DN, Vercauteren F, Houle D, Ducatenzeiler A, Klein WL, Glabe CG, Szyf M, Cuello AC: Transgenic mice as a model of pre-clinical Alzheimer’s disease. Curr Alzheimer Res 2011, 8:4-23.
• [103]Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR: Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng 2001, 17:157-165.
• [104]Liu Y, Yoo MJ, Savonenko A, Stirling W, Price DL, Borchelt DR, Mamounas L, Lyons WE, Blue ME, Lee MK: Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer’s disease. J Neurosci 2008, 28:13805-13814.